Constellium Lifts 2026 Outlook on Record Q2 EBITDA, Pulls Forward 2028 Targets
CSTM has more than doubled off its 52-week low of $13.04.
Summary
Constellium posted record Q2 2026 Adjusted EBITDA of $439 million and raised full-year guidance, now expecting to achieve its 2028 financial targets two years early.
Key Events · Earnings and Guidance · CSTM
-
Record Q2 Adjusted EBITDA
Adjusted EBITDA reached $439 million, up 201% YoY, including a $129 million non-cash metal price lag benefit. Segment Adjusted EBITDA hit a record $310 million.
-
Raised Full-Year 2026 Guidance
Management now expects Adjusted EBITDA of $980 million–$1.020 billion (excluding metal price lag) and Free Cash Flow above $300 million, achieving 2028 targets two years ahead of schedule.
-
Strong Free Cash Flow and Shareholder Returns
Generated $90 million in Free Cash Flow in Q2 and repurchased $20 million in shares. Leverage improved to 1.8x, within the target range.
-
Debt Reduction
Completed a $100 million partial redemption of 5.625% Senior Notes due 2028 in July, leaving $225 million outstanding.
Analysis · CSTM · Manufacturing
A record quarterly Adjusted EBITDA of $439 million, fueled by broad-based segment strength and a $129 million non-cash metal price lag benefit, underscores the quarter's standout performance. More importantly, management raised full-year 2026 Adjusted EBITDA guidance to $980 million–$1.020 billion and Free Cash Flow to over $300 million, pulling forward its 2028 targets by two years. The combination of accelerating earnings, debt reduction, and continued buybacks signals strong operational momentum and financial discipline, though the large non-cash metal price lag component warrants attention.
At the time of this filing, CSTM was trading at $30.05 on NYSE in the Manufacturing sector, with a market capitalization of approximately $4B. The 52-week trading range was $13.04 to $36.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.